{"id":"ima203","safety":{"commonSideEffects":[{"rate":null,"effect":"Cytokine release syndrome"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Infusion-related reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IMA203 is a bispecific antibody construct that simultaneously binds to CD3 on T cells and to PRAME (preferentially expressed antigen in melanoma), a tumor-associated antigen present on various cancers. By bridging T cells directly to PRAME-expressing tumor cells, it activates and redirects cytotoxic T-cell killing against cancer cells. This approach leverages the patient's own immune system to target malignant cells.","oneSentence":"IMA203 is a T-cell engager that redirects patient T cells to recognize and kill cancer cells expressing the PRAME antigen.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:33.294Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"PRAME-positive melanoma"},{"name":"PRAME-positive solid tumors"}]},"trialDetails":[{"nctId":"NCT03686124","phase":"PHASE1, PHASE2","title":"ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors","status":"RECRUITING","sponsor":"Immatics US, Inc.","startDate":"2019-05-14","conditions":"Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult","enrollment":375},{"nctId":"NCT06743126","phase":"PHASE3","title":"SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma","status":"RECRUITING","sponsor":"Immatics US, Inc.","startDate":"2025-01-14","conditions":"Melanoma, Cutaneous Malignant","enrollment":360},{"nctId":"NCT06946225","phase":"PHASE1","title":"ACTengine® IMA203 Combined With mRNA-4203","status":"RECRUITING","sponsor":"Immatics US, Inc.","startDate":"2025-07-25","conditions":"Cutaneous Melanoma, Synovial Sarcoma","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["anzutresgene autoleucel","anzu-cel"],"phase":"phase_3","status":"active","brandName":"IMA203","genericName":"IMA203","companyName":"Immatics US, Inc.","companyId":"immatics-us-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"IMA203 is a T-cell engager that redirects patient T cells to recognize and kill cancer cells expressing the PRAME antigen. Used for PRAME-positive melanoma, PRAME-positive solid tumors.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}